Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its multicenter, ...
The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...
In a rare and inspiring medical achievement, a hospital in Navi Mumbai has successfully saved a micro-preemie born at just 23 ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Merit Medical Systems, ...
Ibuprofen again failed to improve short-term outcomes when used to close patent ductus arteriosus (PDA) in newborns, the placebo-controlled Baby-OSCAR trial showed. Administered parenterally a few ...
An extremely premature infant, medically classified as a micro-preemie, a term used for babies born before 26 weeks of ...
Merit Medical Systems, Inc. MMSI, on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback